Resistant herpes simplex virus infection and HIV: A potential diagnostic and therapeutic dilemma

Laboratory Medicine

Volumn 42, Issue 8, 2011, Pages 452-457

  Bush, Larry M ^a,b   Talledo Thais, Karla ^b   Casal Fernandez, Alyn ^c   Perez, Maria T ^d  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JACKSON MEMORIAL HOSPITAL   (United States)

^d JFK Medical Center   (United States)

Author keywords

Acyclovir; Anti viral resistance; Famciclovir; Foscarnet; Herpes simplex virus; HIV AIDS

Indexed keywords

ACICLOVIR; FOSCARNET; LEVOFLOXACIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENITAL ULCER; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MIXED INFECTION; PERIANAL ABSCESS; PERINEUM; SOFT TISSUE INFECTION; ULCER HEALING; VIRUS INFECTION; VIRUS RESISTANCE; WESTERN BLOTTING;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 79961149872     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMMVWC1EX7AW8ZMD     Document Type: Article

References (30)

1. Hutfield DC. History of herpes genitalis. Brit J Vener Dis. 1966;42:263-268.
2. Nahmias AJ, Josey WE, Naib ZM, et al. Antibodies to Herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. Am J Epidemiol. 1970;91:547-552.
3. Leo J. The new scarlet letter. Time Magazine. 1982;120.
4. Lafferty WE, Downey L, Celum C, et al. Herpes simplex virus type 1 as a cause of genital herpes: Impact on surveillance and prevention. J Infect Dis. 2000;181:1454-1457.
5. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med. 2003;163:76-80.
6. Strick LB, Wald A, Celum C. Management of herpes simplex virus 2 infection in HIV type 1-infected persons. Clin Infect Dis. 2006;43:347-356.
7. Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs. 2007;67:155-174.
8. Duffus WA, Mermin J, Bunnell R, et al. Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS. 2005;16:733-735.
9. Reynolds SJ, Quinn TC. Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2. Infect Dis Clin North Am. 2005;19:415-425.
10. Palù G, Benetti L, Calistri A. Molecular basis of the interactions between herpes simplex viruses and HIV-1. Herpes. 2001;8:50-55.
11. Bevilacqua F, Marcello A, Toni M, et al. Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient. J Acquir Immune Defic Syndr. 1991;4:967-969.
12. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: A review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445.
13. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med. 1992;326:1533-1539.
14. Strick LB, Wald A. Diagnostics for herpes simplex virus: Is PCR the new gold standard? Mol Diagn Ther. 2006;10:17-28.
15. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(suppl 2):S173-S182.
16. Philip SS, Ahrens K, Shayevich C, et al. Evaluation of a new point-of-care serologic assay for herpes simplex virus type 2 infection. Clin Infect Dis. 2008;47:e79-e82.
17. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA. 1977;74:5716-5720.
18. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.
19. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the transmission of genital herpes. N Engl J Med. 2004;350:11-20.
20. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199-226.
21. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 2003;16:569-596.
22. Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-128.
23. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol. 2004;42:242-249.
24. Shin YK, Cai GY, Weinberg A, et al. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol. 2001;39:913-917.
25. Sauerbrei A, Deinhardt S, Zell R, et al. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res. 2010;86:246-252.
26. Field HJ. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin Virol. 2001;21:261-269.
27. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003;26:29-37.
28. Tebas P, Scholl D, Jollick J, et al. A rapid assay to screen for drug-resistant herpes simplex virus. J Infect Dis. 1998;177:217-220.
29. Thi TN, Deback C, Malet I, et al. Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR. Antiviral Res. 2006;69:152-157.
30. Horsburgh BC, Chen SH, Hu A, et al. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: Can strain differences compensate for loss of thymidine kinase in pathogenesis? J Infect Dis. 1998;178:618-625.